Non-Current Liabilities
Long-Term Debt
Merck & Co. Long-Term Debt decreased by 0.4% to $49.1B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 41.1%, from $34.8B to $49.1B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt shows an upward trend with a 9.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 4, 2026
How to read this metric
High levels of long-term debt increase financial leverage and interest risk, while lower levels provide more flexibility but may indicate under-utilization of cheaper debt capital.
Detailed definition
This represents the portion of debt obligations that are due beyond one year, serving as a primary source of long-term c...
Peer comparison
Large-cap pharmaceutical companies often carry significant long-term debt to fund R&D and acquisitions, balanced by strong cash flows.
Metric ID:
long_term_debtHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $26.5B | $26.4B | $33.1B | $31.8B | $31.7B | $30.4B | $30.7B | $30.7B | $36.9B | $34.9B | $35.1B | $34.2B | $37.8B | $38.1B | $37.1B | $34.8B | $35.4B | $41.4B | $49.3B | $49.1B |
| QoQ Change | — | -0.4% | +25.4% | -3.9% | -0.3% | -4.1% | +1.0% | +0.0% | +20.2% | -5.4% | +0.6% | -2.6% | +10.5% | +0.8% | -2.6% | -6.2% | +1.7% | +16.9% | +19.1% | -0.4% |
| YoY Change | — | — | — | — | +19.6% | +15.2% | -7.3% | -3.5% | +16.4% | +14.8% | +14.3% | +11.4% | +2.4% | +9.2% | +5.7% | +1.8% | -6.3% | +8.7% | +32.9% | +41.1% |
Range$26.4B – $49.3B
CAGR+13.9%
Avg YoY Growth+11.0%
Median YoY Growth+10.3%
Long-Term Debt at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s long-term debt?
- Merck & Co. (MRK) reported long-term debt of $49.1B in Q1 2026.
- How has Merck & Co.'s long-term debt changed year-over-year?
- Merck & Co.'s long-term debt increased by 41.1% year-over-year, from $34.8B to $49.1B.
- What is the long-term trend for Merck & Co.'s long-term debt?
- Over 5 years (2020 to 2025), Merck & Co.'s long-term debt has grown at a 9.2% compound annual growth rate (CAGR), from $31.8B to $49.3B.
- What does long-term debt mean?
- The total amount of debt the company owes that is not due for repayment within the next year.